[go: up one dir, main page]

EA201890360A1 - Соединение, нацеленное на ил-23a и фактор активации в-лимфоцитов (baff), и его применение - Google Patents

Соединение, нацеленное на ил-23a и фактор активации в-лимфоцитов (baff), и его применение

Info

Publication number
EA201890360A1
EA201890360A1 EA201890360A EA201890360A EA201890360A1 EA 201890360 A1 EA201890360 A1 EA 201890360A1 EA 201890360 A EA201890360 A EA 201890360A EA 201890360 A EA201890360 A EA 201890360A EA 201890360 A1 EA201890360 A1 EA 201890360A1
Authority
EA
Eurasian Patent Office
Prior art keywords
baff
lymphocytes
application
activation factor
compound targeting
Prior art date
Application number
EA201890360A
Other languages
English (en)
Inventor
Санджайа Сингх
Ци Пань
Рейчел Ребекка Барретт
Лесли С. Джонсон
Панкадж Гупта
Сара Лоу
Хайся У
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Мэкроудженикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх, Мэкроудженикс, Инк. filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201890360A1 publication Critical patent/EA201890360A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)

Abstract

Изобретение относится к соединениям, специфичным к ИЛ-23А и ФАВЛ (BAFF), композициям, содержащим указанные соединения, и способам их применения. Также раскрыты нуклеиновые кислоты, клетки и способы получения, связанные с указанными соединениями и композициями.
EA201890360A 2015-07-23 2016-07-21 Соединение, нацеленное на ил-23a и фактор активации в-лимфоцитов (baff), и его применение EA201890360A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562196170P 2015-07-23 2015-07-23
US201562201067P 2015-08-04 2015-08-04
US201662355302P 2016-06-27 2016-06-27
PCT/US2016/043267 WO2017015433A2 (en) 2015-07-23 2016-07-21 Compound targeting il-23a and b-cell activating factor (baff) and uses thereof

Publications (1)

Publication Number Publication Date
EA201890360A1 true EA201890360A1 (ru) 2018-06-29

Family

ID=57835236

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890360A EA201890360A1 (ru) 2015-07-23 2016-07-21 Соединение, нацеленное на ил-23a и фактор активации в-лимфоцитов (baff), и его применение

Country Status (22)

Country Link
US (3) US10280231B2 (ru)
EP (1) EP3322436A4 (ru)
JP (1) JP6866345B2 (ru)
KR (1) KR102644875B1 (ru)
CN (1) CN108135976B (ru)
AU (1) AU2016297575B2 (ru)
BR (1) BR112018001255A2 (ru)
CA (1) CA2993329A1 (ru)
CL (1) CL2018000182A1 (ru)
CO (1) CO2018001264A2 (ru)
EA (1) EA201890360A1 (ru)
IL (1) IL256665B2 (ru)
MX (1) MX2018000959A (ru)
MY (1) MY191081A (ru)
NZ (2) NZ778160A (ru)
PE (1) PE20180774A1 (ru)
PH (2) PH12021552628A1 (ru)
SA (1) SA518390788B1 (ru)
SG (1) SG10201912593VA (ru)
TW (2) TWI861413B (ru)
UA (1) UA125433C2 (ru)
WO (1) WO2017015433A2 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
CA2816950C (en) 2010-11-04 2018-11-27 Boehringer Ingelheim International Gmbh Anti-il-23 antibodies
MX368653B (es) 2012-05-03 2019-10-10 Boehringer Ingelheim Int Anticuerpos anti-il-23p19.
US10507241B2 (en) 2014-07-24 2019-12-17 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of IL-23A related diseases
MX2018000959A (es) * 2015-07-23 2018-06-06 Boehringer Ingelheim Int Compuesto que se dirige a il-23a y al factor de activacion de linfocitos b (baff) y usos de estos.
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
TW202323304A (zh) * 2021-09-30 2023-06-16 大陸商江蘇恆瑞醫藥股份有限公司 抗ｉｌ２３抗體融合蛋白及用途
TW202442678A (zh) * 2022-12-28 2024-11-01 大陸商蘇州創勝醫藥集團有限公司 包含抗-baff抗體的雙特異性結合蛋白及其用途
WO2025007943A1 (zh) * 2023-07-06 2025-01-09 荣昌生物制药(烟台)股份有限公司 用taci-fc融合蛋白治疗anca相关性血管炎的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (ja) 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2281842A1 (en) 2000-06-16 2011-02-09 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
AU2006236439B2 (en) 2005-04-15 2012-05-03 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
EP2097452A1 (en) * 2006-12-14 2009-09-09 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
CN104788563A (zh) 2007-12-21 2015-07-22 米迪缪尼有限公司 白介素-4受体α(IL-4Rα)-173的结合成员
KR101603917B1 (ko) 2008-05-09 2016-03-17 애브비 인코포레이티드 최종 당화 산물의 수용체(ｒａｇｅ)에 대한 항체 및 이의 용도
PL2786762T3 (pl) 2008-12-19 2019-09-30 Macrogenics, Inc. Kowalencyjne diabody i ich zastosowania
US20130129723A1 (en) * 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
GB201002238D0 (en) * 2010-02-10 2010-03-31 Affitech As Antibodies
PL3053932T3 (pl) * 2010-02-19 2021-03-08 Xencor, Inc. Nowe immunoadhezyny CTLA4-IG
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
BR112013002533A2 (pt) * 2010-08-02 2021-09-08 Macrogenics, Inc Polipeptídeo de ligação de proteína sérica e diacorpo complexado ao polipeptídeo de ligação de proteína sérica
CA2816950C (en) * 2010-11-04 2018-11-27 Boehringer Ingelheim International Gmbh Anti-il-23 antibodies
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
KR101941514B1 (ko) 2010-12-22 2019-01-23 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 개선된 반감기를 가지는 변형된 항체
CA2830254C (en) * 2011-03-16 2019-09-10 Amgen Inc. Fc variants
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
ES2676031T3 (es) 2012-02-15 2018-07-16 F. Hoffmann-La Roche Ag Cromatografía de afinidad basada en el receptor Fc
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
AR090626A1 (es) * 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos
US9708401B2 (en) * 2012-05-22 2017-07-18 Bristol-Myers Squibb Company IL-17A/F cross-reactive monoclonal antibodies and methods of using the same
KR102181776B1 (ko) * 2012-06-05 2020-11-24 삼성전자주식회사 범용 디바이스에서의 파일 송/수신 장치 및 방법
WO2014100490A1 (en) * 2012-12-19 2014-06-26 Adimab, Llc Multivalent antibody analogs, and methods of their preparation and use
JP2015088330A (ja) * 2013-10-30 2015-05-07 トヨタ自動車株式会社 硫黄含有全固体電池
US10435474B2 (en) * 2013-12-24 2019-10-08 Ossianix, Inc. Baff selective binding compounds and related methods
AU2015315834B2 (en) * 2014-01-31 2019-12-12 Boehringer Ingelheim International Gmbh Novel anti-BAFF antibodies
MX2018000959A (es) * 2015-07-23 2018-06-06 Boehringer Ingelheim Int Compuesto que se dirige a il-23a y al factor de activacion de linfocitos b (baff) y usos de estos.

Also Published As

Publication number Publication date
WO2017015433A3 (en) 2017-03-09
IL256665B1 (en) 2023-06-01
IL256665B2 (en) 2023-10-01
WO2017015433A2 (en) 2017-01-26
UA125433C2 (uk) 2022-03-09
US20170022294A1 (en) 2017-01-26
SG10201912593VA (en) 2020-02-27
NZ778160A (en) 2025-05-02
TW202144411A (zh) 2021-12-01
TWI861413B (zh) 2024-11-11
MX2018000959A (es) 2018-06-06
SA518390788B1 (ar) 2021-12-26
US20210107998A1 (en) 2021-04-15
US10280231B2 (en) 2019-05-07
TW201712030A (zh) 2017-04-01
KR102644875B1 (ko) 2024-03-06
PE20180774A1 (es) 2018-05-07
CN108135976A (zh) 2018-06-08
PH12021552628A1 (en) 2022-06-27
TWI733685B (zh) 2021-07-21
US10844138B2 (en) 2020-11-24
CL2018000182A1 (es) 2018-08-31
EP3322436A4 (en) 2019-03-27
PH12018500151A1 (en) 2018-07-30
AU2016297575A1 (en) 2018-02-15
KR20180028522A (ko) 2018-03-16
CO2018001264A2 (es) 2018-05-10
NZ738942A (en) 2025-05-02
EP3322436A2 (en) 2018-05-23
JP2018527323A (ja) 2018-09-20
IL256665A (en) 2018-02-28
MY191081A (en) 2022-05-30
US20190241678A1 (en) 2019-08-08
BR112018001255A2 (pt) 2018-09-11
CN108135976B (zh) 2022-10-18
JP6866345B2 (ja) 2021-04-28
CA2993329A1 (en) 2017-01-26
US11884744B2 (en) 2024-01-30
AU2016297575B2 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
EA201890360A1 (ru) Соединение, нацеленное на ил-23a и фактор активации в-лимфоцитов (baff), и его применение
EA201891211A1 (ru) Ингибиторы cxcr2
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
PH12018500718A1 (en) Compounds useful as modulators of trpm8
EA201891338A1 (ru) Композиции и способы для иммуноонкологии
MX2020009401A (es) Ligadores de nucleótidos modificados.
EA202092435A3 (ru) Моноклональные антитела против bcma
EA201891209A1 (ru) Модуляторы хемокиновых рецепторов
EA201890373A1 (ru) Пиридиновые соединения, пригодные для борьбы с фитопатогенными грибами
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
MX378288B (es) Inhibidores de pirimidina del fgfr4.
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201600124A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
EA201890572A1 (ru) Биофармацевтические композиции
EA201790570A1 (ru) Модуляторы р2х7
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
BR112016029510A2 (pt) métodos para a preparação de um composto, e, composto intermediário.
CL2016001488A1 (es) Quinazolin-thf-aminas como inhibidores de pde1
EA201791645A1 (ru) Новые соли и полиморфы scy-078
BR112016027455A2 (pt) moduladores ppar
EA201890177A1 (ru) Мультиспецифические связывающие белки